Minimal residual disease (MRD) testing plays a crucial role in the management of patients with cancers such as acute lymphoblastic leukemia, multiple myeloma, and acute myeloid leukemia. By detecting tiny amounts of remaining cancer cells that cannot be clinically observed, MRD testing can help clinicians assess treatment response and make important decisions about further treatment. A positive...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian